Christopher Evans, M.D., FACS

Christopher P. Evans, M.D., FACS

Specialties

Cancer

Urologic Oncology

Urology

Department

Urology

Title

  • Chair, Department of Urology
  • Professor
To see if Christopher P. Evans is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Lawrence J. Ellison Ambulatory Care Center

4860 Y St., Suite 2200
Sacramento, CA 95817
Driving Directions

Primary Phone:
916-734-2222

UC Davis Comprehensive Cancer Center

2279 45th Street
Sacramento, CA 95817
Driving Directions

Primary Phone:
800-362-5566
916-734-5959

4501 X St.
Sacramento, CA 95817
Driving Directions

Primary Phone:
800-362-5566

Additional Phone Numbers

Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Philosophy of Care

Dr. Evans' philosophy of care is to:

  • fully assess the patient's medical condition, including how it relates to family and social circumstances;
  • educate the patient fully about their disease process; and
  • include the patient in the decision-making process that best suits the outcomes they seek.

In each case he looks for opportunity to enroll them in any new therapies or clinical trials that may be available and pertinent.

Clinical Interests

Dr. Evans' practice is dedicated to the management of patients with urologic malignancies. He works with medical oncologists and radiation oncologists to provide multimodal approaches to cancer therapy.

His surgical expertise includes robotic assisted laparoscopic radical prostatectomy with nerve sparing, complex renal surgery to include partial nephrectomy and vena cava thrombectomy, cystectomy with extended pelvic lymph node dissection and urinary diversion with orthotopic neobladders.

Dr. Evans also has expertise in treating patients with metastatic testicular cancer and performing retroperitoneal lymph node dissection in post chemotherapy patients.

Research/Academic Interests

Dr. Evans' research laboratory focuses on prostate cancer; specifically, mechanisms signaling the androgen receptor to activate prostate cancer growth and progression following castration. His laboratory has developed models to study this and has identified novel mechanisms that activate the androgen receptor.

His laboratory work has tested new agents and brought them from bench studies to animal models to clinical trials.

Division

Urology

Center/Program Affiliation

Robotic Surgery Program
UC Davis Comprehensive Cancer Center

Education

M.D., F.A.C.S., Dartmouth Medical School, Hanover NH 1986

B.A., University of Vermont, Burlington VT 1981

Residency

Surgery, UC San Francisco, San Francisco CA 1990-1991

Urology, UC San Francisco, San Francisco CA 1991-1995

Fellowships

University of California, San Francisco National Kidney Foundation Research Fellow, San Francisco CA 1993-1994

Urologic Oncology, University of Texas, Anderson Cancer Center, Houston TX 1995-1997

Board Certifications

American Board of Urology, 2009

American College of Surgeons, 2000

National Board of Medical Examiners, 1987

Professional Memberships

American Association for Cancer Research

American Association for the Advancement of Science

American Association of Genitourinary Surgeons

American College of Surgeons

American Society of Clinical Oncology

American Urology Association

Association of Military Surgeons of the United States

European Association of Urology

Society for Basic Urologic Research

Society of Government Urologists

Society of Urologic Oncology

Southwest Oncology Group

Uniformed Services University

Honors and Awards

American Association of Genitourinary Surgeons, Elected Membership, 2009

Western Section AUA nominee for the Gold Cystoscope Award, 2005

1st Prize, Joseph F. McCarthy Essay Contest of the American Urological Association, 2003

Finalist, California Cancer Research Program Gerald P. Murphy Award, 2001

Honorable Mention, AUA Circon/ACMI Essay Contest, Laboratory Research, 1996

First Place Award for Basic Science, Society for University Urology Residents, National Chief Resident Meeting, 1995

Recipient, American Association for Cancer Research Young Investigator Award, ?Basic and Clinical Aspects of Prostate Cancer?, 1994

Recipient, American Association for Cancer Research/National Cancer Institute Travel Grant, Molecular Biology, Aspen, CO, 1993

Recipient, Army Commendation Medal, 1990

Finalist, Army Science Conference Competition, 1990

Select Recent Publications

To view a detailed list of Dr. Evans' publications, please click here.

Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, Miller K, Kim CS, Kimura G, Armstrong AJ, Sternberg CN, Loriot Y, de Bono J, Noonberg SB, Mansbach H, Bhattacharya S, Perabo F, Beer TM, Tombal B. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 Oct:70(4):675-683.

Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW. ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016 May 22;22(5):488-96.

Chandrasekar T, Yang JC, Gao AC, Evans CP. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015 Sep 1;13:206.

Nguyen, HG, Tilki, D, Dall'Era, MA, Durbin-Johnson, B, Carballido, JA, Chandrasekar, T, Chromecki, T, Ciancio, G, Daneshmand, S, Gontero, P, Gonzalez, J, Haferkamp, A, Hohenfellner, M, Huang, WC, Espinós, EL, Mandel, P, Martinez-Salamanca, JI, Master, VA, McKiernan, JM, Montorsi, F, Novara, G, Pahernik, S, Palou, J, Pruthi, RS, Rodriguez-Faba, O, Russo, P, Scherr, DS, Shariat, SF, Spahn, M, Terrone, C, Vergho, D, Wallen, EM, Xylinas, E, Zigeuner, R, Libertino, JA, Evans, CP. Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. J Urol. 2015.

Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP, Gao AC. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res. 2015 Apr 1;75(7):1413-22. Epub 2015 Feb 3.

Tilki, D, Hu, B, Nguyen, HG, Dall'Era, MA, Bertini, R, Carballido, JA, Chandrasekar, T, Chromecki, T, Ciancio, G, Daneshmand, S, Gontero, P, Gonzalez, J, Haferkamp, A, Hohenfellner, M, Huang, WC, Koppie, TM, Linares, E, Lorentz, CA, Mandel, P, Martinez-Salamanca, JI, Master, VA, Matloob, R, McKiernan, JM, Mlynarczyk, CM, Montorsi, F, Novara, G, Pahernik, S, Palou, J, Pruthi, RS, Ramaswamy, K, Faba, OR, Russo, P, Shariat, SF, Spahn, M, Terrone, C, Thieu, W, Vergho, D, Wallen, EM, Xylinas, E, Zigeuner, R, Libertino, JA, Evans, CP. Impact of Synchronous Metastasis Distribution on Cancer-Specific Survival in Renal Cell Carcinoma After Radical Nephrectomy with Tumor Thrombectomy. J of Urol. Feb;193(2):436-42.

Jin C, Yang L, Xie M, Lin C, Merkurjev D, Yang JC, Tanasa B, Oh S, Zhang J, Ohgi KA, Zhou H, Li W, Evans CP, Ding S, Rosenfeld MG. Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens. Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9235-40.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; the PREVAIL Investigators. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. N Engl J Med. 2014 Jul 31;371(5):424-33.

Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 2014 Jun 15;20(12):3198-210.

Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN Jr, DeVere White RW, Gao AC, Evans CP. Targeting Autophagy Overcomes Enzalutamide Resistance in Castratration-Resistant Prostate Cancer Cells and Improves Therapeutic Response in a Xenograft Model. Oncogene. 2014 Sep 4;33(36):4521-30.